Thorne Healthtech, Inc. (THRN) SEC Filing 10-Q Quarterly Report for the period ending Thursday, June 30, 2022

Exhibit 99.1

Thorne HealthTech Reports First Quarter 2022 Results

Reaffirms Full-Year 2022 Guidance

NEW YORK, May 11, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. (“Thorne HealthTech” or the “Company”) (NASDAQ:

Highlights:

“Our solid first quarter performance was driven by robust growth across sales channels,” said Paul Jacobson, Thorne HealthTech’s chairman and CEO. “More health professionals, sports organizations, and individuals are becoming aware of the science-backed solutions we offer that help optimize performance and inform personalized decisions that can lead to a longer, healthier life. With the recent launch of our healthy aging campaign, positive results from the OneDraw blood collection device study and upcoming product launches, we are strengthening our position in each of our end markets.”

Net Sales

The following table provides a summary of sales by channel for the three months ended March 31, 2022, compared to the three months ended March 31, 20211:

1 “Professional” is generally in reference to our network of health professionals; and “B2B” is generally in reference to business-to-business customers.

As of March 31, 2022, the Company’s number of active subscriptions grew 57.0% to approximately 265,000, compared to approximately 168,000 as of March 31, 2021. The Company continued to experience high customer retention, recurring purchases, and low customer acquisition costs. For each of the three months ended March 31, 2022 and 2021, the Company’s annual life-time value (“LTV”) to customer acquisition cost (“CAC”) ratio was 6.2x.

Cost of Sales and Gross Profit

The following table provides a summary of cost of sales and gross profit for the three months ended March 31, 2022, compared to the three months ended March 31, 2021:

1